返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Scientific India Attends Annual Arthroplasty Conference Hyderabad

[2018-03-29] 

Hyderabad, India – From February 24 to February 25, MicroPort® Scientific India attended the Annual Arthroplasty Conference Hyderabad in India with more than 400 orthopedic surgeons from worldwide in attendance. MicroPort® Scientific India displayed MicroPort® Orthopedics products and attracted wide attention from the audience with its SuperPath® Micro-posterior Total Hip Arthroplasty ("SuperPath®") and ADVANCE® Total Knee Replacement System ("ADVANCE®").
 
On February 24, during the session of "Hip Surgical Technique", Australian orthopedic expert Dr. Sol Qurashi delivered a speech of "posterior approach – SuperPath®". He pointed out, SuperPath® features early healing, less intraoperative blood loss, and fast postoperative recovery. Meanwhile, Dr. Sol Qurashi completed a live hip replacement surgery with SuperPath®. The surgery achieved successful result and the advantages of SuperPath® won high recognition from the audience.
 
On the same day, MicroPort® Scientific India hosted a training course about the design rationale of ADVANCE®. Dr. Sanjay from Indian hospital Kokilaben hospital Mumbai demonstrated the design rationale and clinical application of ADVANCE®. After the demonstration, the surgeons were allowed to try implanting ADVANCE® one by one, and most of them spoke highly of the excellent performance of ADVANCE® as it is more stable compared to traditional PS knees.
 
Since the establishment of MicroPort® Scientific India in 2016, it has introduced Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firefighter™ PTCA Balloon Catheter ("Firefighter™") to the India market. With the increasing awareness of MicroPort® brand in the local market, its cardiovascular products are gaining higher recognition among patients and physicians in India. As a country with the second largest population, India has a fast growing orthopedic market. According to statistics, in 2016 the market value of Indian orthopedic implant stood at USD375 million with an annual growth rate of 20% from 2017 to 2020. The appearance of MicroPort® Scientific India in the First Hyderabad Arthroplasty Meeting was reported by several local media such as The Hans India, Surya, The Hindu Business Line, Aadab Hyderabad. With the expansion of the orthopedic business in India, it is expected that the market share and brand awareness of MicroPort® will be further increased in India and other overseas market.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Attends MD&M WEST 2018
[Next]:Firehawk® Gains Regulatory Approval in Myanmar